These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37335960)

  • 21. Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial.
    Cavallaro G; Grassi A; Pavoni C; Micò MC; Busca A; Cavattoni IM; Santarone S; Borghero C; Olivieri A; Milone G; Chiusolo P; Musto P; Saccardi R; Patriarca F; Pane F; Saporiti G; Rivela P; Terruzzi E; Cerretti R; Marotta G; Carella AM; Nagler A; Russo D; Corradini P; Bernasconi P; Iori AP; Castagna L; Mordini N; Oldani E; Di Grazia C; Bacigalupo A; Rambaldi A
    Blood Cancer J; 2024 Aug; 14(1):141. PubMed ID: 39168989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
    Liu H; Fan ZP; Jiang QL; Huang F; Zhou HS; Zhang X; Yu GP; Wu MQ; Sun J; Liu QF
    Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Saraceni F; Labopin M; Brecht A; Kröger N; Eder M; Tischer J; Labussière-Wallet H; Einsele H; Beelen D; Bunjes D; Niederwieser D; Bochtler T; Savani BN; Mohty M; Nagler A
    J Hematol Oncol; 2019 Apr; 12(1):44. PubMed ID: 31023346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine.
    Kikuchi T; Mori T; Ohwada C; Onoda M; Shimizu H; Yokoyama H; Onizuka M; Koda Y; Kato J; Takeda Y; Hino Y; Mishina T; Sakaida E; Shono K; Nagao Y; Yokota A; Matsumoto K; Morita K; Okamoto S;
    Int J Hematol; 2021 Jan; 113(1):128-133. PubMed ID: 32886279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
    Pagliardini T; Castagna L; Harbi S; Porta MD; Rey J; Fürst S; Bramanti S; Saillard C; Legrand F; Maisano V; Faucher C; Granata A; Hospital MA; Lining W; Weiller PJ; Calmels B; Charbonnier A; Lemarie C; Chabannon C; Vey N; Mokart D; Blaise D; Devillier R
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1803-1809. PubMed ID: 31128325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
    Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens.
    Versluys AB; Boelens JJ; Pronk C; Lankester A; Bordon V; Buechner J; Ifversen M; Jackmann N; Sundin M; Vettenranta K; Abrahamsson J; Mellgren K
    Bone Marrow Transplant; 2021 Jun; 56(6):1426-1432. PubMed ID: 33469191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial.
    Liu H; Huang F; Zhang Y; Wu M; Xu N; Fan Z; Sun Z; Li X; Lin D; Xiong Y; Liu X; Lin R; Shi P; Xu J; Wang Z; Li X; Sun J; Liu Q; Xuan L
    Am J Hematol; 2023 Mar; 98(3):408-412. PubMed ID: 36588387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
    Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
    Murthy GSG; Kim S; Estrada-Merly N; Abid MB; Aljurf M; Assal A; Badar T; Badawy SM; Ballen K; Beitinjaneh A; Cerny J; Chhabra S; DeFilipp Z; Dholaria B; Perez MAD; Farhan S; Freytes CO; Gale RP; Ganguly S; Gupta V; Grunwald MR; Hamad N; Hildebrandt GC; Inamoto Y; Jain T; Jamy O; Juckett M; Kalaycio M; Krem MM; Lazarus HM; Litzow M; Munker R; Murthy HS; Nathan S; Nishihori T; Ortí G; Patel SS; Van der Poel M; Rizzieri DA; Savani BN; Seo S; Solh M; Verdonck LF; Wirk B; Yared JA; Nakamura R; Oran B; Scott B; Saber W
    Haematologica; 2023 Jul; 108(7):1900-1908. PubMed ID: 36779595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
    Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
    Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
    Bredeson CN; Zhang MJ; Agovi MA; Bacigalupo A; Bahlis NJ; Ballen K; Brown C; Chaudhry MA; Horowitz MM; Kurian S; Quinlan D; Muehlenbien CE; Russell JA; Savoie L; Rizzo JD; Stewart DA
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):993-1003. PubMed ID: 18721762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies.
    Cai X; Wei J; He Y; Yang D; Jiang E; Huang Y; Han M; Feng S
    Int J Clin Pharm; 2015 Feb; 37(1):44-52. PubMed ID: 25432692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial.
    Zhang W; Gui R; Zu Y; Zhang B; Li Z; Zhang Y; Wang X; Guo S; Zhan X; Fu Y; Song Y; Zhou J
    Br J Haematol; 2023 Jan; 200(2):210-221. PubMed ID: 36200642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin.
    Yeh AC; O'Donnell PV; Schoch G; Martin PJ; McFarland C; McCune JS; Cooper JP; Doney K; Flowers MED; Sorror ML; Appelbaum FR; Storer BE; Gooley T; Deeg HJ
    Bone Marrow Transplant; 2022 Feb; 57(2):198-206. PubMed ID: 34741096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
    Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
    Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.